Marinus Pharmaceuticals Inc (NASDAQ:MRNS) has a beta value of 1.25 and has seen 0.42 million shares traded in the recent trading session. The company, currently valued at $17.31M, closed the recent trade at $0.31 per share which meant it lost -$0.01 on the day or -3.15% during that session. The MRNS stock price is -3532.26% off its 52-week high price of $11.26 and 16.13% above the 52-week low of $0.26. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.1 million shares traded. The 3-month trading volume is 2.48 million shares.

The consensus among analysts is that Marinus Pharmaceuticals Inc (MRNS) is Buy stock at the moment, with a recommendation rating of 2.40. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 2 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) trade information

Sporting -3.15% in the red today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the MRNS stock price touched $0.31 or saw a rise of 8.82%. Year-to-date, Marinus Pharmaceuticals Inc shares have moved -97.11%, while the 5-day performance has seen it change 1.98%. Over the past 30 days, the shares of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) have changed -16.04%. Short interest in the company has seen 5.66 million shares shorted with days to cover at 1.09.

Wall Street analysts have a consensus price target for the stock at $3, which means that the shares’ value could jump 89.67% from the levels at last check today. The projected low price target is $2.0 while the price target rests at a high of $6.0. In that case, then, we find that the latest price level in today’s session is -1835.48% off the targeted high while a plunge would see the stock gain -545.16% from the levels at last check today.

Marinus Pharmaceuticals Inc (MRNS) estimates and forecasts

Figures show that Marinus Pharmaceuticals Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -79.64% over the past 6 months, with this year growth rate of 22.81%, compared to 16.70% for the industry.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 6.04% over the past 5 years. Earnings growth for 2024 is a modest 23.04% while over the next 5 years, the company’s earnings are expected to increase by 20.00%.

MRNS Dividends

Marinus Pharmaceuticals Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Marinus Pharmaceuticals Inc (NASDAQ:MRNS)’s Major holders

Insiders own 10.94% of the company shares, while shares held by institutions stand at 83.04% with a share float percentage of 93.24%. Investors are also buoyed by the number of investors in a company, with Marinus Pharmaceuticals Inc having a total of 108.0 institutions that hold shares in the company. The top two institutional holders are TANG CAPITAL MANAGEMENT LLC with over 4.8 million shares worth more than $5.62 million. As of 2024-06-30, TANG CAPITAL MANAGEMENT LLC held 8.443% of shares outstanding.

The other major institutional holder is SOFINNOVA INVESTMENTS, INC., with the holding of over 4.15 million shares as of 2024-06-30. The firm’s total holdings are worth over $4.86 million and represent 7.3025% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Franklin Strategic Series-Franklin Biotechnology Discove. As of Jun 30, 2024, the former fund manager holds about 3.14% shares in the company for having 1.73 shares of worth $0.54 million while later fund manager owns 1.2 shares of worth $0.38 million as of Jul 31, 2024, which makes it owner of about 2.18% of company’s outstanding stock.